Evotec updates analyst coverage, shares tracked against biotech peers
26.06.2026 - 14:09:15 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-26, 14:08.
Evotec SE (DE0005664809) remains on analysts' radar as the German drug discovery specialist continues to stabilize operations after a 2023 cyberattack and a 2024 Nasdaq delisting, according to recent research comments. The Hamburg-based group is still compared with European biotech peers such as MorphoSys and Sartorius in sector coverage.
What recent reports highlight
Recent analyst and market commentary underline that Evotec is rebuilding investor confidence after a challenging 2023, when a cyberattack disrupted operations and delayed reporting, as documented in company communications. A subsequent decision to delist Evotec American Depositary Shares from Nasdaq in 2024 has shifted the focus back to its primary listing in Frankfurt and trading on Xetra, which remains the main venue for the stock.
In their latest sector pieces, biotech analysts emphasize Evotec's role as a contract research and development partner for large pharmaceutical companies, noting multi-year collaborations with groups such as Bristol Myers Squibb and Novo Nordisk that underpin medium-term revenue visibility. Some reports mention Evotec alongside contract development peers when discussing outsourcing trends, even though the company maintains a distinct focus on early-stage discovery and preclinical work rather than large-scale manufacturing.
How consensus views remain shaped
Consensus assessments collected over recent months show that research houses still see Evotec as a structurally important player in the European biotech services landscape, with ratings spread between Buy and Hold and reflecting both the growth potential and the execution risks following the past disruptions. Price targets in these reports vary depending on assumptions about contract ramp-ups and margin normalization, but analysts consistently point to the company’s partnered pipeline and service backlog as key valuation drivers.
Market commentators also note that Evotec shares tend to trade with higher volatility than the broader Stoxx Europe 600, reflecting the combination of project-based revenues and sensitivity to news flow on collaborations or pipeline milestones. For comparison, more mature life-science suppliers such as Sartorius typically show a different risk profile, focusing on recurring equipment and consumables sales, while Evotec’s revenues depend more directly on research project volumes and milestone achievements.
All news and analysis on the Evotec SE shares
Follow current reports, background pieces and regulatory disclosures on Evotec SE for a broader view of the biotech services specialist.
The product behind the stock
Evotec’s business centers on outsourced drug discovery and preclinical development services for pharmaceutical and biotechnology clients, supported by proprietary technology platforms in areas such as small molecules, biologics and iPSC-based cell models. These platforms enable partners to advance candidates more efficiently in the early stages of research and development.
Where the stock trades today
Evotec SE shares trade primarily in Frankfurt and on Xetra in euros, with investors monitoring the stock alongside other European biotech and life-science names.
Evotec SE at a glance
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Trading venue: Xetra
- Price (as of 2026-06-26, 14:08): [value] EUR
- Market cap: [value] EUR (as of 2026-06-26)
- Sector / industry: Biotechnology / Drug discovery services
- Index membership: not a member of a major blue-chip index
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
